Section: Miscellaneous

Review Article

REBALANCING THE GUT ECOSYSTEM: A COMPREHENSIVE REVIEW OF FAECAL MICROBIOTA TRANSPLANTATION

Mehnaz Khan[1], Bishouno Bhowmick[3], Sharique Ahmad,[2] Pankaj Sachdeva[4], Md Ibrahim[1], Priyesh Srivastava[1]

[1]*Junior Resident, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow, Uttar Pradesh, India.*
[2]*Professor, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow, Uttar Pradesh, India.*
[3]*Assistant Professor, Pharmacology & GP, American University of Barbados School of Medicine, Wildey, Bridgetown, Saint Michael, BB11100, Barbados.*
4th Year Medical student, American University of Barbados School of Medicine, Wildey, Bridgetown, Saint Michael, BB11100, Barbados.

Received *: 05/11/2024*
Received in revised form *: 17/12/2024*
Accepted *: 02/01/2025*

Corresponding Author:
Dr. Mehnaz Khan,
Junior Resident, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow, Uttar Pradesh, India.
Email: ayushigupta1220@gmail.com

DOI: 10.70034/ijmedph.2025.1.16

Source of Support: Nil,
Conflict of Interest: None declared

Int J Med Pub Health
2025; 15 (1); 89-97

ABSTRACT

The faecal microbiota, an intricate and diverse community of bacteria found in the gastrointestinal tract, is vital to human well-being. Microbes of this kind, which include fungi, bacteria, viruses, and archaea, support a number of essential functions, including as immune system regulation, vitamin synthesis, and digestion. The faecal microbiota is implicated in various illnesses and is essential to maintaining health. The advancements in bioinformatics and sequencing technology have allowed for a greater understanding of its composition, variety, and functionality. Firmicutes and Bacteroidetes make up the bulk of the bacteria in the gut microbiota, with Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobacteria following in order of abundance. These bacterial populations are influenced by age, diet, genetics, antibiotic use, and environment; higher diversity is typically associated with better health. Short-chain fatty acids (SCFAs), are produced when firmicutes, such as Lactobacillus and Clostridium, digest food fibers. SCFAs are critical for gut health. Prevotella and other members of the Bacteroidetes family are essential for the breakdown of complex carbohydrates. Similar to Bifidobacterium, actinobacteria are good for gut health, especially in young children. Although they are less common, proteobacteria include dangerous species like Salmonella and Escherichia, while verrucomicrobia—most notably, Akkermansia muciniphila—help to maintain a healthy gut lining and have anti-inflammatory qualities. The gut microbiota is the target of several therapeutic interventions, including antibiotic stewardship, faecal microbiota transplantation (FMT), probiotics, and prebiotics. Prebiotics and probiotics have the power to improve health outcomes by re-establishing microbial balance. The gut microbiota may be precisely altered by novel therapies such as next-generation probiotics, synbiotics, and drugs that target the microbiome. The gut microbiota-brain link, the microbiome-gut-brain axis, and the role of microorganisms in cancer treatment will be the focus of future research. The effectiveness of medicines targeting the microbiota will be improved by personalized medicine approaches that take individual microbial patterns into account.

Keywords: Fecal Microbiota, Gut Microbiota, Microbiota-Health Interaction, Short-Chain Fatty Acids (SCFAs), Fecal Microbiota Transplantation (FMT), Microbiota-Targeted Therapies.

INTRODUCTION

The complex microbial community known as the faecal microbiota, which resides in the gastrointestinal system, is crucial to maintaining the wellness of people. These microbes, which include fungi, bacteria, viruses, and archaea, provide essential functions such immune system modulation, vitamin synthesis, and digestion.[1] Recent developments in bioinformatics and sequencing technology have greatly increased our comprehension of the structure, variety, and role of the faecal microbiota.[2] The present study aims to provide an in-depth analysis of the faecal microbiota, with a focus on its role in health and illness, possible therapeutic applications, and future research directions. Microbes that are not bacteria also have important roles. Methanobrevibacter smithii is one of the archaea that helps with digestion since it produces methane by eating hydrogen. The dynamics of the bacterial population are influenced by the intestinal virome, which is composed of eukaryotic viruses and bacteriophages, whilst fungi, such as species of Saccharomyces and Candida, affect gut health and disease states.[3] The immune system, vitamin synthesis, gut barrier maintenance, digestion, and metabolism all depend on the gut bacteria. In order to produce metabolites like SCFAs that feed colonocytes and control metabolism, microbes help break down complex proteins, lipids, and carbohydrates.[4] In order to enhance immunological tolerance and defense against infections, microbial metabolites and cell wall constituents interact with the host immune system. Important vitamins including B12, K, and folate are produced by some gut bacteria.[5] Additionally, the microbiota maintains the strength of the intestinal barrier by preventing toxicants and harmful microorganisms from translocating.

COMPOSITION AND DIVERSITY

The majority of bacteria, specifically Firmicutes and Bacteroidetes, comprise the human gut biome. Other significant phyla include Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobacteria. Within these phyla, numerous genera and species contribute to the intricate ecosystem[6]. The diversity of the faecal microbiota is influenced by several factors, such as antibiotic use, genetics, age, nutrition, and environment. Reduced diversity is connected to a number of disorders, whereas a diverse microbiota is generally associated with health.[7]

BACTERIAL COMMUNITY STRUCTURE

- **Firmicutes**: Within the gut microbiota, the phylum Firmicutes is a dominant and varied group that includes species like Ruminococcus, Lactobacillus, and Clostridium. Due to their metabolic processes, especially the fermentation of food fibres, these bacteria are essential for preserving gut health.[8]
  - Clostridium: Several species in the genus Clostridium are anaerobic fermenters that use complex carbohydrates as a source of the compound butyrate along with other short-chain fatty acids (SCFAs). Colonocytes, the cells lining the colon, depend on butyrate as a major source of energy and for maintaining the functioning of the intestinal barrier. Spore production is another way that Clostridium species maintain their resilience and durability in the gut environment.[9]
  - Lactobacillus: Well-known probiotics called Lactobacillus species ferment carbohydrates to produce lactic acid. This lactic acid reduces the pH of the gut, which stops harmful bacteria from growing. Furthermore, Lactobacillus species contribute to overall gut health and infection prevention by improving the gut mucosal barrier, regulating the immune system, and producing antimicrobial substances.[10]
  - Ruminococcus: Ruminococcus species break down complex plant polysaccharides like cellulose and hemicellulose into simpler sugars that other bacteria can produce. This breakdown is necessary for the efficient digestion and utilization of dietary fibers in order to generate SCFAs such as acetate and butyrate. Through their ability to regulate inflammation and give colonocytes energy, these SCFAs promote gut health.[11]
- **Bacteroidetes:** The phylum Bacteroidetes comprises a large fraction of the microbiota in the gastrointestinal tract, with species such as Bacteroides and Prevotella acting as its principal representatives. These microbes are essential for general metabolic activities, intestinal health, and for the absorption of complex carbohydrates.[12]
  - Bacteroides: acteroides species are very effective in breaking down complex polysaccharides, such as starches, glycoproteins, and dietary fibers. Their extensive range of carbohydrate-active enzymes (CAZymes) enables them to digest a variety of substrates. This enzyme activity results in the production of short-chain fatty acids (SCFAs), which feed the host and support colon health. Examples of these SCFAs are acetate and propionate. Bacteroides aid in the gut's general energy balance and nutritional absorption by digesting carbohydrates. Additionally, they are involved in the production of several important vitamins, including vitamin K and several B vitamins.[13]
  - PrevotellaPlant-derived polysaccharides, such as xylans and pectins, are known to be broken down by Prevotella species. People that consume high amounts of plant-based fiber in their diets are more likely to have these bacteria. Among the SCFAs produced by prevotella is propionate, which has been linked to beneficial effects on metabolism like improved blood sugar

regulation and reduced inflammation. Prevotella is more common in people that eat a high-fibre, plant-based diet; this relationship between prevalence and diet is well-established. This illustrates how diet affects the gut microbiota's composition and physiological output.[14]

- **Actinobacteria**: The genus Bifidobacterium, in particular, belongs to the phylum Actinobacteria and is important for gut health maintenance in both adults and newborns.
  - One of the earliest bacteria to colonize the baby's digestive system is Bifidobacterium species, which are transferred from the mother during childbirth and nursing. They are skilled at fermenting complex carbohydrates, such as dietary fibers for adults and human milk oligosaccharides (HMOs) for infants.[15]
  - Infant Gut Health: Bifidobacterium supports a microbiota that is balanced and aids in the digestion of heterocyclic amines (HMOs), which helps newborns' immune systems grow. These bacteria help to prevent the colonization of dangerous bacteria by decreasing the alkaline status of the gut environment through the generation of acetic and lactic acids.[16]
  - Adult Gut Health: Because it ferments dietary fibers to create short-chain lipids (SCFAs) like butyrate and acetate, Bifidobacterium still has positive effects on humans. By providing energy to colonocytes, maintaining the strength of the gut barrier, and lowering inflammatory conditions, these SCFAs improve gut health.[17]
- **Proteobacteria:** The taxonomic group within the gut microbiota, bacteria that are both commensal and pathogenic are grouped together in a diversified way as protobacteria. Proteobacteria can significantly affect gut health despite being less prevalent than other phyla, especially when it comes to pathogenic species like Salmonella and Escherichia.[18]
  - Escherichia: Among the members of this genus, Escherichia coli (E. coli) is a well-known species that includes both pathogenic and benign strains. Commensal E. Coli strains contribute to gut homeostasis, protect against pathogen colonization through competitive exclusion, and produce vitamin K. Enteropathogenic (EPEC) and enterohemorrhagic (EHEC) are two pathogenic E. Coli strains that can cause gastrointestinal disorders. In addition to causing diarrhea, abdominal pain, and, in extreme situations, systemic infections, these bacteria also create toxins and virulence factors that damage the intestinal lining.[19]
- Salmonella: One of the main pathogenic species in this genus is Salmonella enterica. Foodborne infections such as fever, diarrhea, and cramping in the abdomen can be caused by it. A salmonella infection is brought on by tainted food or drink, and it causes sickness by invading and inflaming the intestinal lining and interfering with regular gut functions.[20]
- **Verrucomicrobia:** errucomicrobia is a lesser-known phylum of Gram-negative microorganisms that is present in soil, freshwater environments, the human gut, and other diverse environments. Verrucomicrobia are distinctive in that they resemble warts and are involved in several biological processes, such as the cycling of carbon and the oxidation of methane. Their reduction of complex organic waste enhances soil fertility and plant health. Genera that support the preservation of gut health include those linked to antiinflammatory qualities and metabolic regulation in the human gut. Verrucomicrobia are being studied more and more, which is exposing their ecological significance as well as possible advantages for human health and environmental sustainability.[21]

Non-Bacterial Microbes

Apart from bacteria, the gut microbiota also consists of viruses, fungi, and archaea:

1. **Archaea**: Microorganisms known as archaea cohabit with bacteria and eukaryotic germs in the human gut microbiome. They contribute significantly to the metabolism and gut ecology by aiding in the digestion of intricate carbohydrates and producing methane as a byproduct. Methanogens are a kind of archaea that live in anaerobic environments and influence fermentation processes and microbial diversity, which benefits gut health.[22] Archaea have been studied less than bacteria, although their effects on human health are becoming more widely acknowledged. These effects may include obesity and gastrointestinal diseases. To fully comprehend their consequences for human well-being, more investigation is needed into their unique roles and interactions within the gut ecosystem.[22]
2. **Viruses**: In the gut microbiota, viruses predominate over bacterial cells, especially bacteriophages. These viruses infect bacteria, changing the dynamics and variety of microorganisms in the gut. They are essential for controlling bacterial populations, passing on genes, and determining the makeup of the microbiome. By altering bacterial processes linked to immunity, disease resistance, and metabolism, gut viruses can have an effect on human health. Virome, the virus that makes up the microbiome of one's gut, is highly dynamic and unique; it responds to shifts in the environment, diet, and state of health. To fully appreciate gut viruses' function in preserving gut homeostasis and their possible therapeutic benefits, one must have a thorough understanding of them.[23]
3. **Fungi**: Coexisting with bacteria, viruses, and archaea in the gut microbiota are fungi, an

essential but little-understood component. They aid in the process of digestion and intake of nutrients while maintaining the natural equilibrium of the digestive system. Aspergillus species, Saccharomyces, and Candida are common intestinal fungi. These fungi interact with the immune system by controlling inflammatory responses and potentially influencing conditions such as bowel inflammation and irritable bowel syndrome. Fungal imbalance, or dysbiosis, can result in diseases and overgrowth. The specific functions of gut fungus, their relationships with other microbes, and their consequences for human health are still being investigated.[24]

ROLE IN HEALTH

The fecal microbiota performs several critical functions that contribute to host health:

1. **Digestion and Metabolism**: The faecal microbiota, which is made up of various bacteria, viruses, fungi, and archaea, is essential to digestion and metabolism. As a result of their assistance in breaking down complex proteins, lipids, and carbohydrates that are indigestible to humans, gasses and short-chain fatty acids are produced as byproducts. These metabolites affect the immune system, control gut pH, and supply energy. In addition, the microbiome facilitates the absorption of minerals and synthesizes important vitamins like B and K. Dysbiosis, or imbalances in faecal microbiota, is linked to gastrointestinal illnesses, metabolic problems, and general health issues, underscoring the significance of these microbiota imbalances in preserving metabolic homeostasis.[25]
2. **Immune Modulation**: Fecal microbiota has a major impact on host health and immunological regulation. They support tolerance to helpful bacteria and aid in immune system regulation, protecting the body from infections. For instance, gut bacteria produce metabolites called short-chain fatty acids that regulate immune cell function and inflammation. Furthermore, they support the production of antimicrobial peptides, which prevent harmful bacteria from entering the circulation, and preserve the strength of the intestinal barrier. Dysbiosis, or a disorder in the microbiota, can lead to immunological dysregulation, which can exacerbate conditions like allergies, autoimmune illnesses, and inflammatory bowel disease. Thus, a healthy and well-functioning immune system depends on a balanced gut microbiota.[26]
3. **Vitamin Production**: A vital function of faecal microbiota is to produce vitamins, which are vital for the health of the host. Vitamins including vitamin K and the B-vitamins (B12, B6, biotin, and folate) are produced by certain gut bacteria. These vitamins are essential for a number of body processes, including as blood coagulation, energy metabolism, and the preservation of healthy neurons and skin. Vitamin production can be hampered by disruptions in the gut flora, which can result in shortages and related health problems. Therefore, maintaining enough vitamin synthesis and general health depends on having a balanced and healthy gut microbiota. [27]
4. **Barrier Function:** The faecal microbiota is essential to the health of the host and is necessary for the gut barrier to function. They contribute to the strengthening of the gut lining by encouraging the creation of mucus and junction-forming proteins, which seal the membrane of the gut. This barrier prevents harmful germs and toxins from entering the bloodstream. Dysbiosis, a disturbance in the microbiota, can lead to increased gut permeability, inflammation, and illnesses such as leaky gut syndrome, which can damage the barrier. Therefore, overall health and a strong gut barrier depend on a healthy microbiota.[28]

MECHANISMS OF ACTION

1. Short-Chain Fatty Acids (SCFAs): Butyrate, propionate, and acetate are among the significant metabolites known as short-chain fatty acids (SCFAs), which are produced when the intestinal microbiota ferments food fibers. Both intestine and overall health are dependent on these SCFAs.[29]

- Acetate: Acetate is the most common SCFA in the bowels and bloodstream. The primary producers of it are Bifidobacterium along with other fiber-fermenting bacteria. Muscle cells and peripheral tissues utilise acetate as an energy source. Through central nervous system signaling, it also contributes to appetite regulation.[30]
- Propionate: The majority of propionate is produced by Bacteroides species. It is absorbed by the bloodstream and transported to the liver, where it participates in the gluconeogenic process, which produces sugar from sources that are not carbohydrates. By affecting immune cell activity and preventing the synthesis of pro-inflammatory cytokines, propionate also demonstrates anti-inflammatory qualities.[31]
- Butyrate: Butyrate is produced by firmicutes, particularly Clostridia species. It is crucial for maintaining the strength of the digestive barrier and provides the colonocytes—the cells lining the colon—with their primary energy source. Moreover, by promoting the growth of T cells that regulate and inhibiting the expression of the protein nuclear factor kappa B (NFκB), a critical inflammatory pathway, butyrate demonstrates potent anti-inflammatory qualities.[32]



Figure 1: Action of short chain fatty acids on various body organs



Figure 2: Microbial metabolites mechanism of action in human body

2. **Microbial Metabolites**: Indoles, bile acids, and trimethylamine-N-oxide (TMAO) are a few examples of microbial metabolites that significantly impact human wellness and metabolism. These substances are generated by the gut microbiota and are essential to many physiological and metabolic processes.[33]

- Bile Acids: Primary bile acids are produced by the liver from lipid and are subsequently stored in the gallbladder. After being secreted into the colon, primary bile acids are transformed into additional bile acids by the gut bacteria. They also serve as signaling molecules, regulating energy expenditure, inflammation, and glucose metabolism through interactions with receptors such the farnesoid X receptor (FXR) and the G-protein coupled bile acid receptor (TGR5).[34]
- Indoles: Tryptophan is broken down by gut bacteria to produce indoles. They maintain the strength of the intestinal lining by promoting the synthesis of proteins from tight junctions and mucins. Additionally, indoles have anti-inflammatory properties and have the ability to control cytokine production, which helps to preserve gut homeostasis and fend off disorders linked to inflammation.[35]
- Trimethylamine-N-oxide (TMAO): TMAO is produced from dietary choline and carnitine by gut microbiota, which convert these compounds to trimethylamine (TMA). TMAO influences cholesterol metabolism, enhances platelet aggregation, and promotes vascular inflammation, contributing to the development of cardiovascular conditions.[36]

PATHOPHYSIOLOGY

1. **Inflammation**: Dysbiosis, or a discrepancy in the gut microbiota, is a common underlying cause of a variety of disorders, including chronic inflammation. Dysbiosis causes proinflammatory bacteria to proliferate excessively in diseases like inflammatory bowel disease (IBD), which in turn sets off immunological reactions. Cytokines and other inflammatory mediators are released during these reactions, harming the intestinal lining and escalating inflammation. The development and severity of illnesses like IBD are exacerbated by this persistent inflammatory state, underscoring the importance of microbiome balance in preserving immunological homeostasis.[37]
2. **Metabolic Endotoxemia:** Systemic inflammation in metabolic endotoxemia is brought on by an increase in lipopolysaccharide (LPS)-producing bacteria in the gastrointestinal tract as a result of dysbiosis. LPS, a portion of the outer covering of Gram-negative bacteria, reaches the bloodstream through a breach in the gut barrier and triggers an immune response. Insulin resistance and obesity are two metabolic diseases that are associated with systemic inflammation. In order to prevent and treat metabolic illnesses, it is critical to maintain the balance of gut microbiota, as shown by our understanding of the function of LPS in metabolic endotoxemia.[38]
3. **Barrier Dysfunction**: A weakened intestinal lining that permits germs and poisons to enter the circulation is known as barrier dysfunction in the gut. Systemic conditions including rheumatoid arthritis (RA) and type 1 diabetes (T1D) are exacerbated by this breach. Similar translocations in RA cause systemic inflammation, which in turn fuels inflammatory reactions and joint inflammation. The relevance

of gut health in the prevention of systemic diseases is highlighted by the necessity of maintaining a healthy gut barrier to stop toxic chemicals from infiltrating and causing autoimmune and inflammatory diseases.[39]

THERAPEUTIC APPLICATIONS

Modulating the gut microbiota offers potential therapeutic avenues:

1. **Probiotics and Prebiotics**: The gut flora may be altered by probiotics and prebiotics, creating novel therapeutic opportunities. Beneficial bacteria like Lactobacillus and Bifidobacterium species are known as probiotics, and they have the ability to improve gut barrier function, modify immunological responses, and restore microbial balance. They are frequently used to prevent antibiotic-associated diarrhea, soothe IBS symptoms, and enhance digestive health. Prebiotics are incomprehensible fibers that encourage the formation of good bacteria in the gastrointestinal tract. Probiotics and prebiotics work together to enhance overall gut function and preserve microbial balance, which can lead to better health outcomes.[40]
2. **Faecal Microbiota Transplantation (FMT)**: Fecal microbiota transplantation (FMT) is a procedure in which the gastrointestinal tract of a patient is exposed to stool from a healthy donor. Correcting the imbalance of bacteria in the gut, which can be brought on by a variety of disorders, most notably recurrent Clostridium difficile infection (CDI), is the aim of this treatment.[41]

STEPS OF FAECAL MICROBIOTA TRANSPLANTATION

Donor Selection:

- Screening: Donors go through a thorough screening process to make sure they are in good health and are clear of illnesses that could be spread through the stool.
- Testing: To check for pathogens such as bacteria, viruses, parasites, and fungi, blood and stool tests are performed

Stool Collection and Preparation:

- Collection: The donor's stool is taken out and placed in a sterile container.
- Processing: To create a liquid suspension, the stool is diluted with saline or another solution and filtered to get rid of solid particles.
- Storage: The stool sample that was prepared can be frozen for later use or utilized fresh.

Recipient Preparation:

- Medical Evaluation: To ascertain the recipient's eligibility for FMT, a comprehensive medical evaluation is performed.
- Pre-procedure Management: Patients may be prescribed antibiotics or other drugs to lessen pre-existing gut flora, depending on the ailment being treated.

Table 1: Flowchart of fecal microbiata transplantation (FMT)

Donor Selection

↓

Screening (Health History, Infectious Diseases, Conditions)

↓

Testing (Blood Tests, Stool Tests)

↓

Stool Collection and Preparation

↓

Collection (Sterile Container)

↓

Processing (Dilution, Filtration)

↓

Storage (Fresh, Frozen)

↓

Recipient Preparation

↓

Medical Evaluation (Suitability for FMT)

↓

Pre-procedure Treatment (Antibiotics, Other Medications)

↓

Administration

↓

(Colonoscopy, Enema, Nasogastric/Nasojejunal Tube, Oral Capsules)

↓

Post-procedure Care

↓

Monitoring (Adverse Reactions, Complications)

↓

Follow-up (Efficacy, Recurrence of Symptoms)

Administration:

• Routes of Administration:

- Colonoscopy: A colonoscope is used to inject the stool suspension straight into the colon.
- Enema: An enema is used to inject the stool suspension into the rectum.

- Nasogastric/Nasojejunal Tube: A tube put via the nose carries the stool suspension to the small intestine.
- Oral Capsules: Stool material that has been encapsulated is swallowed.

Post-procedure Care:

• Monitoring: The recipient is kept an eye out for any difficulties or unfavourable reactions.

• Follow-up: Appointments are made on a regular basis to evaluate the effectiveness of the treatment and keep an eye out for any symptom recurrence.

CLINICAL INDICATIONS FOR FMT

- Recurrent Clostridioides difficile infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Irritable Bowel Syndrome (IBS)
- Metabolic Disorders
- Neuropsychiatric Disorders

Potential Risks and Complications:

- Transmission of infections: There is a chance of spreading infectious pathogens, even though this is rare because of strict screening.
- Adverse reactions: These may include cramps, bloating, and diarrhoea among other gastrointestinal problems.
- Long-term effects: Research is still being done on how changing the gut flora will affect people in the long run.

FMT works well for treating several gastrointestinal disorders, especially recurrent CDI. Careful donor selection, stool preparation, and administration to the recipient are all part of the process, which is then closely monitored and followed up on.[41]

3. **Dietary Interventions**: Dietary interventions are primarily responsible for modifying the gut microbiota's makeup and function. High-fiber, plant-based diets promote the development of beneficial bacteria and a rise in microbial diversity, which leads to the production of short-chain fatty acids (SCFAs), which have been associated with several health advantages. These diets are linked to better metabolic health, less inflammation, and intact intestinal barriers. On the other hand, diets heavy in sugar and fat cause dysbiosis, which is typified by a rise in harmful bacteria and a decrease in microbial diversity. This imbalance can lead to inflammation, irregularities in metabolism, and an increased risk of diseases such as obesity, type 2 diabetes, and cardiovascular ailments. As a result, eating decisions are crucial for preserving a balanced gut microbiota and general health.[42]
4. **Antibiotic Stewardship**: Antibiotic stewardship, or responsible consumption of antibiotics, is essential to preventing dysbiosis and the emergence of antibiotic-resistant bacteria. Abuse and misuse of antibiotics can disrupt the delicate balance of the gut microbiota, causing pathogenic bacteria to proliferate and good bacteria to die off. Long-term health effects from this disruption may include immunological dysregulation, metabolic problems, and an increased risk of infections. By using focused, narrow-spectrum medications and only providing antibiotics when absolutely necessary, healthcare providers can promote overall gut health and maintain the efficacy of antibiotics for later use.[43] They can also assist maintain microbial balance and lower the likelihood of antibiotic resistance.

EMERGING THERAPIES

1. **Next-Generation Probiotics**: The term "next-generation probiotics" describes sophisticated probiotic compositions that surpass the properties of conventional probiotics like Bifidobacterium and Lactobacillus. These include newly discovered bacterial strains with particular medicinal qualities, including Akkermansia muciniphila, which is well-known for its function in preserving the integrity of the gut barrier and metabolic health. Targeting certain health issues like obesity, inflammatory bowel disease, and metabolic disorders is the goal of next-generation probiotics. These probiotics seek to improve overall health outcomes and more specifically target complicated disorders by utilizing state-of-the-art research on gut microbiota to inform therapy decisions.[44]
2. **Microbiota-Targeted Drugs**: Advanced probiotic formulations that surpass conventional probiotics such as Lactobacillus and Bifidobacterium are referred to as next-generation probiotics. These comprise unique bacterial strains with particular medicinal qualities, such the well-known gut barrier and metabolic health-preserving Akkermansia muciniphila strain. Obesity, inflammatory bowel disease, and metabolic disorders are among the problems that next-generation probiotics are intended to treat. These probiotics are designed to improve overall health outcomes and treat complex disorders more specifically by utilizing the most recent knowledge on gut microbiota.[45]
3. **Synbiotics**: Synbiotics are a class of novel therapeutics that improve gut health by combining probiotics, or good bacteria, with prebiotics, or indigestible carbohydrates that feed these bacteria. The goal of synbiotics' synergistic impact is to enhance probiotic colonization and survival in the gastrointestinal system, resulting in improved microbial balance and health advantages. Their goals include boosting immunity, promoting good digestion, and maybe reducing the signs and symptoms of digestive conditions such irritable bowel syndrome and inflammatory bowel disease. Synbiotics offer a holistic strategy for enhancing and promoting gut microbiota and general well-being by integrating these two elements.[46]

FUTURE DIRECTIONS

Technological developments in the fields of metagenomics, metabolomics, and other omics will provide additional insight into the intricate relationships that exist between the host and microbiota. The effectiveness of medicines targeting the microbiota will be improved by personalized medicine approaches that take individual microbial patterns into account. Furthermore, the advancement of synthetic biology techniques and next-generation probiotics holds promise for precise gut microbiota modulation.

CONCLUSION

A dynamic and intricate ecology, the faecal microbiota has significant effects on human health and illness. Its composition, role, and interactions with the host provide new opportunities for treatments and medical study. Technological developments and ongoing research will open the door for creative approaches to using the microbiome to manage illnesses and improve health outcomes. Healthcare could undergo a revolution if microbiota research is incorporated into clinical practice and offers individualized, targeted treatments based on microbial profiles.

REFERENCES

1. Marchesi JR, Adams DH, Fava F, Hermes GDA, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut [Internet]. 2015 Sep 2;65(2):330–9. Available from: https://doi.org/10.1136/gutjnl-2015-309990.
2. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Medicine [Internet]. 2016 Apr 27;8(1). Available from: https://doi.org/10.1186/s13073-016-0307-y.
3. Gupta VK, Paul S, Dutta C. Geography, ethnicity or Subsistence-Specific variations in human microbiome composition and diversity. Frontiers in Microbiology [Internet]. 2017 Jun 23;8. Available from: https://doi.org/10.3389/fmicb.2017.01162.
4. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. European Journal of Nutrition [Internet]. 2017 Apr 9;57(1):1–24. Available from: https://doi.org/10.1007/s00394-017-1445-8.
5. Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nature Immunology [Internet]. 2013 Jun 18;14(7):676–84. Available from: https://doi.org/10.1038/ni.2640.
6. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature [Internet]. 2010 Mar 1;464(7285):59–65. Available from: https://doi.org/10.1038/nature08821.
7. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The Human Microbiome Project. Nature [Internet]. 2007 Oct 1;449(7164):804–10. Available from: https://doi.org/10.1038/nature06244.
8. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms [Internet]. 2019 Jan 10;7(1):14. Available from: https://doi.org/10.3390/microorganisms7010014.
9. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environmental Microbiology [Internet]. 2016 Dec 8;19(1):29–41. Available from: https://doi.org/10.1111/1462-2920.13589.
10. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology [Internet]. 2014 Jun 10;11(8):506–14. Available from: https://doi.org/10.1038/nrgastro.2014.66.
11. Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nature Reviews Gastroenterology & Hepatology [Internet]. 2012 Sep 4;9(10):577–89. Available from: https://doi.org/10.1038/nrgastro.2012.156.
12. Attar N. ZIKA virus circulates in new regions. Nature Reviews Microbiology [Internet]. 2016 Jan 11;14(2):62. Available from: https://doi.org/10.1038/nrmicro.2015.28.
13. Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, Weatherford J, et al. Glycan foraging in vivo by an Intestine-Adapted bacterial symbiont. Science [Internet]. 2005 Mar 25;307(5717):1955–9. Available from: https://doi.org/10.1126/science.1109051.
14. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010 Aug 2;107(33):14691–6. Available from: https://doi.org/10.1073/pnas.1005963107.
15. Bowen WH, Burne RA, Wu H, Koo H. Oral biofilms: pathogens, matrix, and polymicrobial interactions in microenvironments. Trends in Microbiology [Internet]. 2018 Mar 1;26(3):229–42. Available from: https://doi.org/10.1016/j.tim.2017.09.008.
16. Garrido D, Ruiz-Moyano S, Kirmiz N, Davis JC, Totten SM, Lemay DG, et al. A novel gene cluster allows preferential utilization of fucosylated milk oligosaccharides in Bifidobacterium longum subsp. longum SC596. Scientific Reports [Internet]. 2016 Oct 19;6(1). Available from: https://doi.org/10.1038/srep35045.
17. Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing colon bacteria: Importance and strategies for their stimulation in the human gut. Frontiers in Microbiology [Internet]. 2016 Jun 28;7. Available from: https://doi.org/10.3389/fmicb.2016.00979.
18. Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism shapes the gut microbiota. Science [Internet]. 2018 Nov 30;362(6418). Available from: https://doi.org/10.1126/science.aat9076.
19. Stecher B. The roles of inflammation, nutrient availability and the commensal microbiota in enteric pathogen infection. Microbiology Spectrum [Internet]. 2015 Jun 18;3(3). Available from: https://doi.org/10.1128/microbiolspec.mbp-0008-2014.
20. McDonald JE, Smith DL, Fogg PCM, McCarthy AJ, Allison HE. High-Throughput Method for Rapid Induction of Prophages from Lysogens and Its Application in the Study of Shiga Toxin-Encoding Escherichia coli Strains. Applied and Environmental Microbiology [Internet]. 2010 Apr 1;76(7):2360–5. Available from: https://doi.org/10.1128/aem.02923-09.
21. Derrien M, Belzer C, De Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microbial Pathogenesis [Internet]. 2017 May 1; 106:171–81. Available from: https://doi.org/10.1016/j.micpath.2016.02.005.
22. Borrel G, McCann A, Deane J, Neto MC, Lynch DB, Brugère JF, et al. Genomics and metagenomics of trimethylamine-utilizing Archaea in the human gut microbiome. ˜ the œISME Journal [Internet]. 2017 Jun 6;11(9):2059–74. Available from: https://doi.org/10.1038/ismej.2017.72.
23. Shkoporov AN, Hill C. Bacteriophages of the human gut: the "Known unknown" of the microbiome. Cell Host & Microbe [Internet]. 2019 Feb 1;25(2):195–209. Available from: https://doi.org/10.1016/j.chom.2019.01.017.
24. Iliev ID, Underhill DM. Striking a balance: fungal commensalism versus pathogenesis. Current Opinion in

Microbiology [Internet]. 2013 Jun 1;16(3):366–73. Available from: https://doi.org/10.1016/j.mib.2013.05.004.
25. Thursby E, Juge N. Introduction to the human gut microbiota. Biochemical Journal [Internet]. 2017 May 16;474(11):1823–36. Available from: https://doi.org/10.1042/bcj20160510.
26. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell [Internet]. 2014 Mar 1;157(1):121–41. Available from: https://doi.org/10.1016/j.cell.2014.03.011.
27. LeBlanc JG, Milani C, De Giori GS, Sesma F, Van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Current Opinion in Biotechnology [Internet]. 2013 Apr 1;24(2):160–8. Available from: https://doi.org/10.1016/j.copbio.2012.08.005.
28. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut [Internet]. 2019 May 10;68(8):1516–26. Available from: https://doi.org/10.1136/gutjnl-2019-318427.
29. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: Short-Chain fatty acids as key bacterial metabolites. Cell [Internet]. 2016 Jun 1;165(6):1332–45. Available from: https://doi.org/10.1016/j.cell.2016.05.041.
30. Besten GD, Van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research [Internet]. 2013 Sep 1;54(9):2325–40. Available from: https://doi.org/10.1194/jlr.r036012.
31. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer R -j. Review article: the role of butyrate on colonic function. Alimentary Pharmacology & Therapeutics [Internet]. 2007 Oct 26;27(2):104–19. Available from: https://doi.org/10.1111/j.1365-2036.2007.03562.x.
32. Canani, R. B., Costanzo, M. D., Leone, L., Pedata, M., Meli, R., & Calignano, A. (2011). Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology, 17(12), 1519-1528. doi: 10.3748/wjg. v17.i12.1519.
33. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-Gut microbiota metabolic interactions. Science [Internet]. 2012 Jun 8;336(6086):1262–7. Available from: https://doi.org/10.1126/science.1223813.
34. Chiang JYL. Bile acids: regulation of synthesis. Journal of Lipid Research [Internet]. 2009 Oct 1;50(10):1955–66. Available from: https://doi.org/10.1194/jlr.r900010-jlr200.
35. Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4. Immunity [Internet]. 2014 Aug 1;41(2):296–310. Available from: https://doi.org/10.1016/j.immuni.2014.06.014.
36. Tang WHW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. ˜ the œJournal of Clinical Investigation/˜ the œJournal of Clinical Investigation [Internet]. 2014 Oct 1;124(10):4204–11. Available from: https://doi.org/10.1172/jci72331.
37. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nature Reviews Gastroenterology & Hepatology [Internet]. 2017 Jul 19;14(10):573–84. Available from: https://doi.org/10.1038/nrgastro.2017.88.
38. Cani P, Delzenne N. The role of the gut microbiota in energy metabolism and metabolic disease. Current Pharmaceutical Design [Internet]. 2009 May 1;15(13):1546–58. Available from: https://doi.org/10.2174/138161209788168164.
39. Fasano A. Intestinal permeability and its regulation by Zonulin: diagnostic and therapeutic implications. Clinical Gastroenterology and Hepatology [Internet]. 2012 Oct 1;10(10):1096–100. Available from: https://doi.org/10.1016/j.cgh.2012.08.012.
40. Gibson, G. R., & Hutkins, R. (2016). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology, 14(8), 491-502. doi: 10.1038/nrgastro.2017.75.
41. Kelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Smith, M., & Telford, S. (2014). Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. American Journal of Gastroenterology, 109(7), 1065-1071. doi: 10.1038/ajg.2014.133.
42. Sonnenburg ED, Sonnenburg JL. The ancestral and industrialized gut microbiota and implications for human health. Nature Reviews Microbiology [Internet]. 2019 May 15;17(6):383–90. Available from: https://doi.org/10.1038/s41579-019-0191-8.
43. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic Advances in Drug Safety [Internet]. 2014 Oct 16;5(6):229–41. Available from: https://doi.org/10.1177/2042098614554919.
44. Ray K. Clearance of nanomaterials in the liver. Nature Reviews Gastroenterology & Hepatology [Internet]. 2016 Aug 24;13(10):560. Available from: https://doi.org/10.1038/nrgastro.2016.136.
45. Bennett JM, Reeves G, Billman GE, Sturmberg JP. Inflammation–Nature's Way to Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing "the Epidemic" of Chronic Diseases. Frontiers in Medicine [Internet]. 2018 Nov 27;5. Available from: https://doi.org/10.3389/fmed.2018.00316.
46. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients [Internet]. 2017 Sep 15;9(9):1021. Available from: https://doi.org/10.3390/nu9091021.